Two healthcare stocks ending the week on a high – Respiri and Avita Medical


  • Healthcare players AVITA Medical and Respiri Limited released updates concerning their respective products leading to a notable increase in share price.
  • AVITA Medical secured approval for the expanded use of its RECELL System for treating burn wounds.
  • Respiri registered and secured approval for the sale of wheezo® in the UK market. The Company plans to begin commercialising in the UK in Q4 CY2021.

Two healthcare stocks, AVITA Medical, Inc. (ASX:AVH) and Respiri Limited (ASX:RSH) ended the week on a solid note on the ASX after announcing positive developments regarding their respective products.

Let us look at these positive developments in detail.

INTERESTING READ: ASX ends week at record closing high as inflation jitters fade

US FDA authorises expanded use of RECELL System

Regenerative medicine company AVITA Medical, Inc. (ASX:AVH) has secured approval from the US Food and Drug Administration (FDA). The approval allows the RECELL® System to be extensively used in composition with meshed autografting for treating patients with acute full-thickness thermal burn wounds of every size for pediatric as well as adults.

Source: Copyright © 2021 Kalkine Media

Now, AVH’s RECELL System can more widely help specialists in curing full-thickness burns of all sizes, involving patients who are older than one month.

Moreover, AVH is showing strong dedication towards pursuing and realising the full potential of its innovative regenerative technology platform to tackle other clinical indications where substantial unmet need is present.

The AVH stock closed 10.444% higher at AU$4.970 on 11 June 2021.

Registration & approval of wheezo®

Another ASX-listed healthcare company, Respiri Limited (ASX:RSH) released an upbeat update concerning the registration and approval of wheezo® for sale in the UK market. This significant milestone comes after RHS registered with the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK Competent Authority.

In line with the expectations of MHRA, European Device Solutions (UK) Ltd has been appointed as the UK Responsible Person (UK-RP) by RHS. Moreover, it has also been demonstrated that wheezo® shall operate safely and attain the indicated performance claims for its meant uses.

Image source: Ratanapon Srisuneton,

DO READ: Respiri (ASX:RSH) shares flying high on TerryWhite Chemmart partnership

Notably, RHS can now apply the new UK Conformity Assessed (UKCA) mark on wheezo®, a prerequisite for the approval of products after Brexit and implies conformity with applicable regulatory requirements.

wheezo® is the first smart device to help manage asthma by monitoring wheeze and recording symptoms, signs, triggers, medication use and weather conditions with the help of the eHealth App.

The achievement of this latest milestone fulfils a commercial requirement for wheezo®, as the product is scheduled for launch in the UK in the fourth quarter of the current calendar year.

RHS continues discussions and negotiations with possible commercial and distribution partners in the UK. The final regulatory requirement now allows RHS to begin commercialising wheezo® in the UK in the last quarter of 2021.

The RSH stock closed 6.329% higher at AU$0.084 on 11 June 2021.

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK